|
- STAT6 - Wikipedia
The proteins of STAT family transmit signals from a receptor complex to the nucleus and activate gene expression Similarly as other STAT family proteins, STAT6 is also activated by growth factors and cytokines STAT6 is mainly activated by cytokines interleukin-4 and interleukin-13 [5]
- Kymera Therapeutics Announces Positive Results from BroADen Phase 1b . . .
KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation
- Comprehensive Profiling of STAT6 Degraders: From Binding and Ternary . . .
Signal Transducer and Activator of Transcription 6 (STAT6) is a pivotal transcription factor activated downstream of the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways
- STAT6: A review of a signaling pathway implicated in various diseases . . .
These pathophysiological implications of the STAT6 pathway, its diagnostic or prognostic role in pathology, as well its immunohistochemical detection with different antibodies will be discussed in this review
- Pathology Outlines - STAT6
NAB2::STAT6 fusion occurs secondary to an intrachromosomal inversion of the 12q13 locus, resulting in the fusion protein which relocates to the nucleus
- What is STAT6? - MyPathologyReport
STAT6 (Signal Transducer and Activator of Transcription 6) is a protein found in cells It plays a key role in transmitting signals from outside a cell to its nucleus, where genetic material is stored This signaling helps regulate how cells grow, divide, and respond to their environment
- Highly selective and reversible STAT6 inhibition demonstrates potential . . .
STAT6 inhibition may represent a compelling future therapeutic opportunity for the treatment of asthma, COPD, prurigo nodularis, and other IL-4 IL-13-dependent diseases
- STAT6: A Challenging Target Gains Traction Utilizing Degraders for Th2 . . .
STAT6, once deemed undruggable, is now being targeted through protein degradation This article highlights recent developments including Kymera’s KT‑621, a cereblon-based STAT6 degrader, that has entered Ph 2 and has shown >95% knockdown of STAT6 as well as Th2 biomarker suppression
|
|
|